Literature DB >> 27891777

Maternal autoimmune disease and birth defects in the National Birth Defects Prevention Study.

Meredith M Howley1, Marilyn L Browne1,2, Alissa R Van Zutphen1,2, Sandra D Richardson1, Sarah J Blossom3, Cheryl S Broussard4, Suzan L Carmichael5, Charlotte M Druschel1,2.   

Abstract

BACKGROUND: Little is known about the association between maternal autoimmune disease or its treatment and the risk of birth defects. We examined these associations using data from the National Birth Defects Prevention Study, a multi-site, population-based, case-control study.
METHODS: Analyses included 25,116 case and 9897 unaffected control infants with estimated delivery dates between 1997 and 2009. Information on autoimmune disease, medication use, and other pregnancy exposures was collected by means of telephone interview. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for birth defects with five or more exposed cases; crude ORs and exact 95% CIs were estimated for birth defects with three to four exposed cases.
RESULTS: Autoimmune disease was reported by 373 mothers (279 case and 94 control mothers). The majority of birth defects evaluated were not associated with autoimmune disease; however, a statistically significant association between maternal autoimmune disease and encephalocele was observed (OR, 4.64; 95% CI, 1.95-11.04). Eighty-two mothers with autoimmune disease used an immune modifying/suppressing medication during pregnancy; this was associated with encephalocele (OR, 7.26; 95% CI, 1.37-24.61) and atrial septal defects (OR, 3.01; 95% CI, 1.16-7.80).
CONCLUSION: Our findings suggest maternal autoimmune disease and treatment are not associated with the majority of birth defects, but may be associated with some defects, particularly encephalocele. Given the low prevalence of individual autoimmune diseases and the rare use of specific medications, we were unable to examine associations of specific autoimmune diseases and medications with birth defects. Other studies are needed to confirm these findings. Birth Defects Research (Part A) 106:950-962, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  autoimmune disease; autoimmune medication; birth defects; congenital malformations; pregnancy

Mesh:

Year:  2016        PMID: 27891777      PMCID: PMC5305117          DOI: 10.1002/bdra.23527

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  32 in total

Review 1.  The effects of methotrexate on pregnancy, fertility and lactation.

Authors:  M E Lloyd; M Carr; P McElhatton; G M Hall; R A Hughes
Journal:  QJM       Date:  1999-10

2.  Confidence interval estimation of interaction.

Authors:  D W Hosmer; S Lemeshow
Journal:  Epidemiology       Date:  1992-09       Impact factor: 4.822

3.  Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies.

Authors:  Lorenzo D Botto; Angela E Lin; Tiffany Riehle-Colarusso; Sadia Malik; Adolfo Correa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2007-10

4.  Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases.

Authors:  Seoyoung C Kim; Sonia Hernandez-Diaz
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

5.  Congenital complete heart block: single tertiary centre experience.

Authors:  Jennifer Yan; Suraj K Varma; Atul Malhotra; Samuel Menahem
Journal:  Heart Lung Circ       Date:  2012-06-29       Impact factor: 2.975

Review 6.  Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity.

Authors:  Gilad Twig; Avi Shina; Howard Amital; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2012-01-03       Impact factor: 7.094

7.  Congenital cardiac defects: a possible association of aminopterin syndrome and in utero methotrexate exposure?

Authors:  Kurt D Piggott; Andrea Sorbello; Elise Riddle; William DeCampli
Journal:  Pediatr Cardiol       Date:  2011-02-17       Impact factor: 1.655

8.  Diabetes mellitus and birth defects.

Authors:  Adolfo Correa; Suzanne M Gilboa; Lilah M Besser; Lorenzo D Botto; Cynthia A Moore; Charlotte A Hobbs; Mario A Cleves; Tiffany J Riehle-Colarusso; D Kim Waller; E Albert Reece
Journal:  Am J Obstet Gynecol       Date:  2008-07-31       Impact factor: 8.661

9.  Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group.

Authors:  Nathalie Costedoat-Chalumeau; Zahir Amoura; Jean-Marc Lupoglazoff; Du Le Thi Huong; Isabelle Denjoy; Danièle Vauthier; Djamel Sebbouh; Olivier Fain; Sophie Georgin-Lavialle; Pascale Ghillani; Lucile Musset; Bertrand Wechsler; Pierre Duhaut; Jean-Charles Piette
Journal:  Arthritis Rheum       Date:  2004-10

10.  Maternal exposure to methotrexate and birth defects: a population-based study.

Authors:  April L Dawson; Tiffany Riehle-Colarusso; Jennita Reefhuis; J Fernando Arena
Journal:  Am J Med Genet A       Date:  2014-06-04       Impact factor: 2.802

View more
  1 in total

1.  Maternal exposure to hydroxychloroquine and birth defects.

Authors:  Meredith M Howley; Martha M Werler; Sarah C Fisher; Alissa R Van Zutphen; Suzan L Carmichael; Cheryl S Broussard; Dominique Heinke; Elizabeth C Ailes; Shannon M Pruitt; Jennita Reefhuis; Allen A Mitchell; Marilyn L Browne
Journal:  Birth Defects Res       Date:  2021-07-23       Impact factor: 2.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.